Crestone Announces Positive Data from Phase 2 Clinical Trial of CRS3123 for C. Difficile Infections (CDI)
Primary endpoint met with high rates of clinical cure at day 12 Very low rates of recurrence...
Read MorePrimary endpoint met with high rates of clinical cure at day 12 Very low rates of recurrence...
Read MoreAnnouncement Regarding CRS0540: Crestone, Inc. and Praedicare Inc. Announce the Publication of...
Read MoreJune 8, 2021 – Announcement: Crestone, Inc. joins the Antimicrobials Working Group to Combat...
Read MoreJune 7, 2021 – Announcement: Crestone, Inc. Enrolls First Patient in Phase 2 Clinical Trial...
Read MoreJuly 1, 2020 – Announcement: Crestone, Inc. Secures NIH Funding for Development Through...
Read MoreMay 29, 2020 – Announcement: Crestone, Inc. receives $250,000 Grant from State of Colorado...
Read MoreApr 27, 2020 – Announcement: Crestone, Inc. Secures NIH Funding for Preclinical Development...
Read MoreCFF Funding Secured Crestone, Inc. (Boulder) Secures CFF Funding for Preclinical Development of...
Read MoreSep 12, 2019 – Announcement: Crestone, Inc. Secures NIH Funding for Phase 2 Clinical Trial...
Read MoreCrestone had the opportunity to showcase its innovative research at the 9th AMR Conference in Basel, Switzerland, and ICDS 2024 in Bled, Slovenia.
Interested in helping further our research into novel antibacterial agents? We’d be thrilled to have your help, either as an investor or a team member.
Have a question or comment? Follow the link below to contact us about general inquiries.
Find work in a team-oriented environment at one of the leading Colorado pharma companies.
If you're interested in becoming an investor to help fund our research and development, contact us today.